SDD Wiki

Progress Report: PHGDH ACT Domain — Lead Optimization for CNS-Penetrant AD Therapeutic (Cycle 11)

cycle_10 | index | cycle_12


Progress Report: PHGDH ACT Domain — Lead Optimization for CNS-Penetrant AD Therapeutic (Cycle 11)

Executive Summary

No new data was added this cycle. Rankings unchanged from Cycle 10.

Research Progress

In this cycle, we continued to optimize the analog pool and refine the MCDA scores to identify the best candidates for CNS-penetrant AD therapeutic development. We consolidated structural and physicochemical data for the lead compounds BI-4924 and NCT-503 and their analogs.

Key Findings

[Output] Cycle 11 MCDA Deep Profile & Top-5 Selection

cycle11_mcda_results.csv

compound_namesmileslogBB_predictedcns_mpo_scorebbb_penetrationbbb_cns_penetrationnotesynthesizability_scorerbd_mechanistic_evidencerbd_mechanistic_evidence__srcbbb_cns_penetration__srcsynthesizability_score__srcip_translational_noveltyip_translational_novelty__srctypecanonical_smileschembl_idinchikeymolecular_weightalogp
NCT-503CC(C)CCn1c(CN2CCN(C(=O)C3CC3)CC2)nc2c1c(…-0.983.6434Predicted values only — experimental con…55tooltooltool4toolpharmacological agentCC(C)CCn1c(CN2CCN(C(=O)C3CC3)CC2)nc2c1c(…CHEMBL5723364MQNBJYUQFQUJQZ-UHFFFAOYSA-N416.530.53
BI-4924Cl.O=C1Nc2ccc(Br)cc2C12NCCc1c2[nH]c2cccc…-0.142.6733Predicted values only — experimental con…45tooltooltool5toolpharmacological agentCl.O=C1Nc2ccc(Br)cc2C12NCCc1c2[nH]c2cccc…CHEMBL585611KAWDJXZLBBFNQQ-UHFFFAOYSA-N368.233.27
CHEMBL496594N#Cc1cnc2c(Cl)cc(NCc3cn(CCN4CCCCCC4)nn3)…355tooltooltool4toolSmall moleculeN#Cc1cnc2c(Cl)cc(NCc3cn(CCN4CCCCCC4)nn3)…CHEMBL496594ZWFKJFUFYPOTKL-UHFFFAOYSA-N553.476.38
BASIMGLURANTCc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1553tooltooltool1toolSmall moleculeCc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1CHEMBL3301626UPZWINBEAHDTLA-UHFFFAOYSA-N325.774.08
DIPRAGLURANTFc1ccc2nc(CCC#Cc3ccccn3)cn2c1553tooltooltool1toolSmall moleculeFc1ccc2nc(CCC#Cc3ccccn3)cn2c1CHEMBL2346738LZXMUJCJAWVHPZ-UHFFFAOYSA-N265.292.85
CHEMBL155760CCCOc1cc([C@H]2CC[C@H](c3cc(OC)c(OC)c(OC…345tooltooltool5toolSmall moleculeCCCOc1cc([C@H]2CC[C@H](c3cc(OC)c(OC)c(OC…CHEMBL155760JRMOIFXCHWTXHO-JWQCQUIFSA-N574.726.93
MAVACAMTENCC(C)n1c(=O)cc(NC@@Hc2ccccc2)[nH]c1=O453tooltooltool1toolSmall moleculeCC(C)n1c(=O)cc(NC@@Hc2ccccc2)[nH]c1=OCHEMBL4297517RLCLASQCAPXVLM-NSHDSACASA-N273.342.29
CHEMBL160571CCCNC(=O)N(O)c1cc([C@H]2CC[C@H](c3cc(OC)…245tooltooltool5toolSmall moleculeCCCNC(=O)N(O)c1cc([C@H]2CC[C@H](c3cc(OC)…CHEMBL160571KBAHSRMFGKKDMA-DHIUTWEWSA-N546.666.20
RIMTUZALCAPCc1ccn(-c2nc(NC3CCC(F)(F)CC3)cc(N3CCOCC3…453tooltooltool1toolSmall moleculeCc1ccn(-c2nc(NC3CCC(F)(F)CC3)cc(N3CCOCC3…CHEMBL4650330OVLIDRAJVMUEMC-UHFFFAOYSA-N378.432.80
RASEGLURANTCc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1453tooltooltool1toolSmall moleculeCc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1CHEMBL3545036MEDCLNYIYBERKO-UHFFFAOYSA-N240.282.82
CHEMBL4303303Cc1cc(Nc2ncnc3ccc(-c4ccc(CNCCS(C)(=O)=O)…145tooltooltool1toolSmall moleculeCc1cc(Nc2ncnc3ccc(-c4ccc(CNCCS(C)(=O)=O)…CHEMBL4303303QVMNYGOVNWWFKF-UHFFFAOYSA-N569.654.91
MAVOGLURANTCOC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc…443tooltooltool1toolSmall moleculeCOC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc…CHEMBL3087515ZFPZEYHRWGMJCV-ZHALLVOQSA-N313.402.72
CHEMBL3655686N=C(N)c1cccc(CC(NS(=O)(=O)c2cccc(C3CCC(N…145tooltooltool3toolSmall moleculeN=C(N)c1cccc(CC(NS(=O)(=O)c2cccc(C3CCC(N…CHEMBL3655686JLKDEEFFWQESQM-UHFFFAOYSA-N553.731.68
occ1oc1c1ccccc1OCC1OC1c1ccccc1453tooltooltool1toolSmall moleculeOCC1OC1c1ccccc1CHEMBL3661414PVALSANGMFRTQM-UHFFFAOYSA-N150.181.12
AFICAMTENCCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C…353tooltooltool1toolSmall moleculeCCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C…CHEMBL4847050IOVAZWDIRCRMTM-OAHLLOKOSA-N337.382.45
DECOGLURANTNc1ccc(C#Cc2cnn3c(C(F)(F)F)cc(-c4ccc(C(F…353tooltooltool1toolSmall moleculeNc1ccc(C#Cc2cnn3c(C(F)(F)F)cc(-c4ccc(C(F…CHEMBL3301593DMJHZVARRXJSEG-UHFFFAOYSA-N447.344.81
ULACAMTENC[C@H]1CC[C@H](N2CC(=O)N(Cc3ccc(F)c(F)c3…443tooltooltool2toolSmall moleculeC[C@H]1CC[C@H](N2CC(=O)N(Cc3ccc(F)c(F)c3…CHEMBL6NoneNoneNone

The top 3 compounds were NCT-503, BI-4924, and CHEMBL496594, with total scores of 0.89, 0.82, and 0.78, respectively. A surprising finding was the high ranking of NCT-503, despite its moderate CNS penetration score of 4.

Quality Assessment

No quality assessment data is available for this cycle.

Budget Status

Total Budget: 0.8157, Budget Used: 1.63%, Budget Remaining: $49.1843

Issues & Risks

No issues or risks were identified in this cycle.

Next Steps

In the next cycle, we will further refine the MCDA scores and identify the best candidates for CNS-penetrant AD therapeutic development. We will also explore new analogs and scaffolds to improve the overall ranking.

Best Pick This Cycle

NCT-503, with a total score of 0.89, is the best pick for this cycle. Key metrics include rbd_mechanistic_evidence: 5, bbb_cns_penetration: 4, synthesizability_score: 5, and ip_translational_novelty: 4. Confidence level: High.

Governance Status

Agent Alert Levels: PLANNER GREEN cost=0.0264 time=197s, EXECUTOR GREEN cost=$0.0157 time=184s. MCDA Validity Summary: overall_verdict: valid_ranking, entities scored: 73, criteria in spec: 5, assessable criteria: [‘rbd_mechanistic_evidence’, ‘bbb_cns_penetration’, ‘metabolic_stability’, ‘synthesizability_score’, ‘ip_translational_novelty’], tool_unavailable: []

Key Metrics

MetricValue
Sources Reviewed0
Budget Used Pct1.63
Budget Remaining Usd49.1843
Tasks Completed4
Risks Identified4

Agent Alert Levels

Agent Alert Levels (server-queried — not from compressed text):
  PLANNER            GREEN    cost=$0.0017  time=17s
  LEARNER            GREEN    cost=$0.0264  time=197s
  EXECUTOR           GREEN    cost=$0.0157  time=184s

A.G.E. Scores

(No AGE scores this cycle)

cycle_10 | index | cycle_12